Oncolytics Biotech Inc (ONCY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Oncolytics Biotech Inc stock (ONCY) is currently trading at $0.95. Oncolytics Biotech Inc PS ratio (Price-to-Sales) is 58.60. Analyst consensus price target for ONCY is $5.53. WallStSmart rates ONCY as Sell.
- ONCY PE ratio analysis and historical PE chart
- ONCY PS ratio (Price-to-Sales) history and trend
- ONCY intrinsic value — DCF, Graham Number, EPV models
- ONCY stock price prediction 2025 2026 2027 2028 2029 2030
- ONCY fair value vs current price
- ONCY insider transactions and insider buying
- Is ONCY undervalued or overvalued?
- Oncolytics Biotech Inc financial analysis — revenue, earnings, cash flow
- ONCY Piotroski F-Score and Altman Z-Score
- ONCY analyst price target and Smart Rating
Oncolytics Biotech Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Oncolytics Biotech Inc (ONCY) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Oncolytics Biotech Inc (ONCY) Key Strengths (0)
Supporting Valuation Data
Oncolytics Biotech Inc (ONCY) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 58.6x annual revenue
Very expensive at 1236.3x book value
Very low institutional interest at 2.42%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Oncolytics Biotech Inc (ONCY) Detailed Analysis Report
Overall Assessment
This company scores 9/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 0 register as strengths (avg 0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (58.60), Price/Book (1236.27) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -769.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -769.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ONCY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ONCY's Price-to-Sales ratio of 58.60x sits near its historical average of 58.6x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 58.6x set in Mar 2026, and 0% above its historical low of 58.6x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Oncolytics Biotech Inc (ONCY) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Oncolytics Biotech Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Debt-to-equity ratio of 7.26 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Oncolytics Biotech Inc.
Bottom Line
Oncolytics Biotech Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Oncolytics Biotech Inc(ONCY)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. The company is headquartered in Calgary, Canada.